1. CHEK2-related breast cancer: real-world challenges.
- Author
-
Weis LN, Bychkovsky BL, Hernandez AR, Barroso-Sousa R, and Sandoval RL
- Subjects
- Humans, Female, Middle Aged, Adult, Brazil, Aged, Genetic Testing, Checkpoint Kinase 2 genetics, Breast Neoplasms genetics, Germ-Line Mutation, Genetic Predisposition to Disease
- Abstract
Purpose: Management of cancer risks associated with the CHEK2 gene, a moderate penetrance breast cancer gene, is challenging in real-world practice. Family history, traditional breast cancer risk factors, and specific genetic CHEK2 variants are risk modifiers in this setting and add complexity for surveillance and risk-reduction decisions. Here, we present a case series of Brazilian CHEK2 carriers affected by breast cancer., Methods: Patients evaluated in the Oncogenetics Department of Hospital Sírio-Libanês (Brasília, Brazil) between November 2017 and September 2021, who had a personal history of breast cancer and a germline genetic test with a pathogenic or likely pathogenic CHEK2 variant, were selected for case description. Clinical pearls and knowledge gaps were highlighted for each case., Results: Twelve women were included in this descriptive analysis. All patients had early-stage breast cancer. Most of them were diagnosed with breast cancer prior to age 50 (9/12) and had a close relative affected by breast cancer (9/12). Seven patients harbored intronic pathogenic variants. Clinical pearls included the following: lack of risk estimates for intronic CHEK2 variants among non-European ancestry CHEK2 carriers, environmental exposures as a risk modifier, notable non-breast cancer diagnosis at young ages, incidental germline finding during tumor profiling, breast cancer diagnosis before the recommended age of breast cancer screening, family history of breast cancer as a risk modifier, and clinical outcomes after breast cancer treatment., Conclusions: Improvements in cancer risk assessment and cancer prevention for CHEK2 carriers are still needed to overcome current clinical challenges on the management of these patients., Competing Interests: Declarations. Competing interests: LNW has received honoraria from Libbs, Novartis and Roche and travel accommodations or expenses from Libbs, GSK and Daiichi-Sankyo. Ethical approval: This study was approved by the Institutional Research Ethical Committee of the Hospital Sírio-Libanês (CAAE 21735619.3.0000.5461) and a waiver of informed consent was granted. All clinical and molecular data were de-identified before data sharing and analysis., (© 2025. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2025
- Full Text
- View/download PDF